RT Journal Article
SR Electronic
T1 The Immune-Buffer COVID-19 Exit Strategy that Protects the Elderly
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.12.20193094
DO 10.1101/2020.09.12.20193094
A1 Vered Rom-Kedar
A1 Omer Yaniv
A1 Roy Malka
A1 Ehud Shapiro
YR 2020
UL http://medrxiv.org/content/early/2020/09/14/2020.09.12.20193094.abstract
AB September 12, 2020COVID-19 is a viral respiratory illness, caused by the SARS-CoV-2 virus with frequent symptoms of fever and shortness of breath [1]. COVID-19 has a high mortality rate among elders. The virus has spread world-wide, leading to shut-down of many countries around the globe with the aim of stopping the spread of the disease. To date, there are uncertainties regarding the main factors in the disease spread, so sever social distancing measures and broad testing are required in order to protect the population at risk. With the increasing spread of the virus, there is growing fraction of the general population that may be immune to COVID-19, following infection. This immunised cohort can be uncovered via large-scale screening for the SARS-CoV-2 (Corona) virus and/or its antibodies. We propose that this immune cohort be deployed as a buffer between the general population and the population most at risk from the disease. Here we show that under a broad range of realistic scenarios deploying such an immunized buffer between the general population and the population at risk may lead to a dramatic reduction in the number of deaths from the disease. This provides an impetus for: screening for the SARS-CoV-2 virus and/or its antibodies on the largest scale possible, and organizing at the family, community, national and international levels to protect vulnerable populations by deploying immunized buffers between them and the general population wherever possible.Declarations of interest noneCompeting Interest StatementThe authors have declared no competing interest.Funding StatementISF 1208/16.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Theoretical study, no approval is needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTheoretical study using public available human data.